---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-228639"
form_type: "8-K"
ticker: "RARE"
cik: "0001515673"
company_name: "Ultragenyx Pharmaceutical Inc."
filed_at: "2026-05-18T18:15:14+00:00"
generated_at: "2026-05-18T18:16:58.552510+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Ultragenyx shareholders OK 14.5M-share equity plan; re-elect directors

## Summary
- Third Amended and Restated 2023 Incentive Plan approved; up to 14.5M new shares available plus shares from prior plans.
- Emil Kakkis, Shehnaaz Suliman, Daniel G. Welch re-elected as Class I directors to serve until 2029 Annual Meeting.
- Ernst & Young ratified as independent auditor; advisory 'say-on-pay' proposal passed with 70.9M votes for.
- Director compensation limit set at $900k per year ($1.5M for first year or Chair/Lead Director).

## SEC filing metadata
- accession: 0001193125-26-228639
- form_type: 8-K
- ticker: RARE
- cik: 0001515673
- company_name: Ultragenyx Pharmaceutical Inc.
- filed_at: 2026-05-18T18:15:14+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1515673/000119312526228639/0001193125-26-228639-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1515673/000119312526228639/rare-20260514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-228639
- JSON: https://secwatch.observer/filing/0001193125-26-228639.json
- Plain text: https://secwatch.observer/filing/0001193125-26-228639.txt

## Key facts
- Shareholder Votes
  Ultragenyx Pharmaceutical Inc. shareholders approved Ratification of Selection of Independent Registered Accounting Firm at the 2026-05-14 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-05-14
  source text: Proposal No. 3 – Ratification of Selection of Independent Registered Accounting Firm At the Annual Meeting, the Company’s stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026. The votes on Proposal 3 were as follows: Votes For Votes Against Abstentions 84,551,399 221,802 13,187
  evidence_url: https://www.sec.gov/Archives/edgar/data/1515673/000119312526228639/0001193125-26-228639-index.htm
- Shareholder Votes
  Ultragenyx Pharmaceutical Inc. shareholders approved Approval of the Third A&R 2023 Plan at the 2026-05-14 meeting.
  - Proposal: equity plan
  - Outcome: passed
  - Meeting: 2026-05-14
  source text: Proposal No. 2 – Approval of the Third A&R 2023 Plan At the Annual Meeting, the Company’s stockholders approved the Third A&R 2023 Plan. The votes on Proposal 2 were as follows: Votes For Votes Against Abstentions Broker Non-Votes 50,659,150 22,888,600 26,748 11,211,890
  evidence_url: https://www.sec.gov/Archives/edgar/data/1515673/000119312526228639/0001193125-26-228639-index.htm
- Shareholder Votes
  Ultragenyx Pharmaceutical Inc. shareholders approved Election of Class I Directors at the 2026-05-14 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-05-14
  source text: Proposal No. 1 – Election of Class I Directors At the Annual Meeting, the Company’s stockholders elected the Class I director nominees below to the Company’s Board of Directors to hold office until the 2029 Annual Meeting of Stockholders or until their successors are elected. The votes on Proposal 1 were as follows: Class I Director Nominees Votes For Votes Withheld Broker Non-Votes Emil D. Kakkis, M.D., Ph.D. 72,517,613 1,056,885 11,211,890 Shehnaaz Suliman, M.D. 65,801,638 7,772,860 11,211,890 Daniel G. Welch 66,301,426 7,273,072 11,211,890
  evidence_url: https://www.sec.gov/Archives/edgar/data/1515673/000119312526228639/0001193125-26-228639-index.htm
- Shareholder Votes
  Ultragenyx Pharmaceutical Inc. shareholders approved Advisory (Non-Binding) Vote to Approve Executive Compensation at the 2026-05-14 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2026-05-14
  source text: Proposal No. 4 – Advisory (Non-Binding) Vote to Approve Executive Compensation At the Annual Meeting, the Company’s stockholders voted, on an advisory basis, in favor of a resolution approving the compensation the Company pays to its “named executive officers” as described in the Proxy Statement. The votes on Proposal 4 were as follows: Votes For Votes Against Abstentions Broker Non-Votes 70,945,277 2,594,517 34,704 11,211,890
  evidence_url: https://www.sec.gov/Archives/edgar/data/1515673/000119312526228639/0001193125-26-228639-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.